One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAGINE Study
Latest Information Update: 14 Nov 2023
At a glance
- Drugs Brolucizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms IMAGINE
- Sponsors Novartis Pharmaceuticals
- 07 Nov 2023 Status changed from active, no longer recruiting to completed.
- 09 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2023 Status changed from active, no longer recruiting to recruiting.